

Financial Statements of

**OTTAWA HOSPITAL
RESEARCH INSTITUTE**

Year ended March 31, 2025

OTTAWA HOSPITAL RESEARCH INSTITUTE

Table of Contents

Year ended March 31, 2025

	Page
Independent Auditor's Report	
Financial Statements:	
Statement of Financial Position	1
Statement of Operations	2
Statement of Changes in Net Assets	3
Statement of Cash Flows	4
Notes to Financial Statements	5 - 17



KPMG LLP

150 Elgin Street, Suite 1800
Ottawa, ON K2P 2P8
Canada
Telephone 613 212 5764
Fax 613 212 2896

INDEPENDENT AUDITOR'S REPORT

To the Members of the Ottawa Hospital Research Institute

Opinion

We have audited the financial statements of the Ottawa Hospital Research Institute (the Entity), which comprise:

- the statement of financial position as at March 31, 2025
- the statement of operations for the year then ended
- the statement of changes in net assets for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies

(Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements, present fairly, in all material respects, the financial position of the Entity as at March 31, 2025, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the ***"Auditor's Responsibilities for the Audit of the Financial Statements"*** section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



Page 3

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

KPMG LLP

Chartered Professional Accountants, Licensed Public Accountants

Ottawa, Canada

June 27, 2025

OTTAWA HOSPITAL RESEARCH INSTITUTE


Statement of Financial Position

March 31, 2025, with comparative information for 2024

	Externally restricted	Unrestricted	2025 Total	2024 Total
Assets				
Current assets:				
Cash	\$ –	\$ 31,472,631	\$ 31,472,631	\$ 29,535,012
Short-term investments (note 4(a))	–	7,179,260	7,179,260	7,000,000
Due from The Ottawa Hospital Foundation (note 2(b))	1,166,493	3,495,313	4,661,806	4,814,316
Amounts receivable (note 3)	8,461,442	1,884,493	10,345,935	14,109,630
	9,627,935	44,031,697	53,659,632	55,458,958
Prepaid expenses	389,777	51,230	441,007	820,700
Long-term amounts receivables (note 3)	1,559,104	–	1,559,104	1,169,329
Investments (note 4(b))	133,701,699	11,596,922	145,298,621	131,913,924
Capital assets (note 5)	19,460,749	–	19,460,749	18,848,741
	\$ 164,739,264	\$ 55,679,849	\$ 220,419,113	\$ 208,211,652
Liabilities and Net Assets				
Current liabilities:				
Accounts payable and accrued liabilities	\$ 1,707,371	\$ 893,523	\$ 2,600,894	\$ 3,536,065
Due to The Ottawa Hospital (note 2(a))	–	11,334,571	11,334,571	7,995,440
Unearned income (note 2(a))	389,777	7,000,000	7,389,777	7,857,096
Unexpended research project funding (note 6)	141,681,367	–	141,681,367	137,384,256
	143,778,515	19,228,094	163,006,609	156,772,857
Loan payable to The Ottawa Hospital Foundation (note 2(b))	1,500,000	–	1,500,000	1,500,000
Deferred capital contributions (note 7)	19,372,136	–	19,372,136	18,715,821
	164,650,651	19,228,094	183,878,745	176,988,678
Net assets (note 8):				
Internally restricted	–	22,243,876	22,243,876	22,077,848
Invested in capital assets	88,613	–	88,613	132,920
Unrestricted	–	14,207,879	14,207,879	9,012,206
	88,613	36,451,755	36,540,368	31,222,974
	\$ 164,739,264	\$ 55,679,849	\$ 220,419,113	\$ 208,211,652

See accompanying notes to financial statements.

On behalf of the Board:

 Director

 Director

OTTAWA HOSPITAL RESEARCH INSTITUTE

Statement of Operations

Year ended March 31, 2025, with comparative information for 2024

	Externally restricted	Unrestricted	2025 Total	2024 Total
Revenue:				
Contributions - external funders	\$ 98,992,052	\$ —	\$ 98,992,052	\$ 99,368,787
The Ottawa Hospital				
Foundation (note 2(b)):				
Research and salary	2,716,178	3,319,405	6,035,583	4,756,227
Endowment fund income	737,990	1,328,406	2,066,396	1,306,280
Indirect cost recovery	—	10,805,025	10,805,025	10,578,094
The Ottawa Hospital (note 2(a))	1,000,000	5,131,596	6,131,596	5,079,561
University of Ottawa (note 2(c)):				
Salary support	—	1,947,795	1,947,795	2,098,187
Endowment fund income	—	56,375	56,375	56,375
Medical practice plans	—	7,304,748	7,304,748	7,373,837
Technology transfer program	—	578,208	578,208	285,922
Research ethics board	—	565,314	565,314	570,709
Miscellaneous	—	71,700	71,700	107,471
Investment income (note 4(b)(i))	—	14,970,220	14,970,220	13,472,916
Amortization of deferred capital contributions (note 7)	4,268,299	—	4,268,299	3,242,660
	107,714,519	46,078,792	153,793,311	148,297,026
Expenses:				
Scientific programs	—	25,200,448	25,200,448	24,072,219
General research administration	—	5,918,784	5,918,784	5,916,314
Technology transfer program	—	557,582	557,582	451,621
Hospital services	—	5,420,711	5,420,711	5,044,334
Other research	—	2,266,176	2,266,176	1,737,338
Research ethics board	—	1,353,390	1,353,390	1,424,107
Research project costs (note 6)	103,446,220	—	103,446,220	99,368,787
Amortization of capital assets	4,312,606	—	4,312,606	3,286,966
	107,758,826	40,717,091	148,475,917	141,301,686
Excess (deficiency) of revenue over expenses	\$ (44,307)	\$ 5,361,701	\$ 5,317,394	\$ 6,995,340

See accompanying notes to financial statements.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Statement of Changes in Net Assets

Year ended March 31, 2025, with comparative information for 2024

	Externally restricted	Invested in capital assets	Internally restricted	Unrestricted	2025 Total	2024 Total
Balance, beginning of year	\$ –	\$ 132,920	\$ 22,077,848	\$ 9,012,206	\$ 31,222,974	\$ 24,227,634
Excess (deficiency) of revenue over expenses	(44,307)	–	–	5,361,701	5,317,394	6,995,340
Transfer to internally restricted (Trainee Initiative) (note 8)	–	–	27,278	(27,278)	–	–
Transfer to internally restricted (Clinical Trials Support Unit) (note 8)	–	–	138,750	(138,750)	–	–
Amortization of capital assets	4,312,606	(4,312,606)	–	–	–	–
Purchase of capital assets (note 7)	(4,924,614)	4,924,614	–	–	–	–
Deferred capital contributions received (note 6)	4,924,614	(4,924,614)	–	–	–	–
Amortization of deferred capital contributions (note 7)	(4,268,299)	4,268,299	–	–	–	–
Balance, end of year	\$ –	\$ 88,613	\$ 22,243,876	\$ 14,207,879	\$ 36,540,368	\$ 31,222,974

See accompanying notes to financial statements.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Statement of Cash Flows

Year ended March 31, 2025, with comparative information for 2024

	2025	2024
Cash provided by (used in):		
Operating activities:		
Excess (deficiency) of revenue over expenses	\$ 5,317,394	\$ 6,995,340
Items not involving cash:		
Amortization of capital assets	4,312,606	3,286,966
Amortization of deferred capital contributions	(4,268,299)	(3,242,660)
Unrealized gains on investments (note 4(b))	(6,147,642)	(8,162,991)
Change in non-cash operating working capital:		
Increase in short-term investments	(179,260)	(2,000,000)
Decrease (increase) in due from The Ottawa Hospital Foundation	152,510	(173,266)
Decrease (increase) in amounts receivable	3,763,695	(3,159,425)
Increase in long term amounts receivable	(389,775)	(1,169,329)
Decrease (increase) in prepaid expenses	379,693	(803,466)
Decrease in accounts payable and accrued liabilities	(935,171)	(517,259)
Increase in due to The Ottawa Hospital	3,339,131	6,117,061
Increase (decrease) in unearned income	(467,319)	789,696
Increase in unexpended research project funding	4,297,111	721,343
	9,174,674	(1,317,990)
Financing activities:		
Deferred contributions received (note 6)	4,924,614	3,018,419
Increase in loan payable to The Ottawa Hospital Foundation	—	1,500,000
	4,924,614	4,518,419
Investing activities:		
Net acquisitions of investments (note 4(b))	(7,237,055)	(3,498,923)
Purchase of capital assets	(4,924,614)	(3,018,419)
	(12,161,669)	(6,517,342)
Net increase (decrease) in cash	1,937,619	(3,316,913)
Cash, beginning of year	29,535,012	32,851,925
Cash, end of year	\$ 31,472,631	\$ 29,535,012

See accompanying notes to financial statements.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements

Year ended March 31, 2025

Ottawa Hospital Research Institute (the "Institute") is an independent health research facility closely affiliated with The Ottawa Hospital and the University of Ottawa, committed to excellence in the creation of scientific knowledge that contributes to the prevention, diagnosis, and treatment of human disease. The Institute was incorporated without share capital under the Ontario Corporations Act on December 5, 2000. It began operations on April 1, 2001 as a result of the combination of the Loeb Health Research Institute at The Ottawa Hospital and The Ottawa General Hospital Research Institute. On January 1, 2004, as a result of the integration of the Ottawa Regional Cancer Centre and The Ottawa Hospital, the clinical research activities of the Cancer Centre were absorbed into the Institute.

The Institute is a registered charity under paragraph 149(1)(f) of the Income Tax Act (Canada) and is exempt from income taxes and may issue tax deductible receipts to donors. Furthermore, the Institute has approved research institute status for purposes of clause 37 (1)(a)(ii)(b) of the Act, whereby a donor is eligible for a Scientific Research and Experimental Development (SR&ED) tax credit in the year the contribution is made.

1. Significant accounting policies:

The financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations and include the following significant accounting policies:

(a) Basis of presentation:

On the statement of financial position and the statement of operations, the externally restricted column presents the Institute's assets, liabilities and results of operations related to its research activities that are funded by externally restricted research grants and contributions. The unrestricted column presents the Institute's administrative and non-restricted research operations.

The Institute accounts for its investment in Boreal Biomanufacturing Inc. using the equity method.

(b) Revenue recognition:

The Institute follows the deferral method of accounting for not-for-profit organizations.

The Institute generates revenue through contributions from external funding agencies and related parties.

Contributions receivable are recorded at an estimated realizable value in the period in which the funding agreement is signed. Unrestricted contributions are recorded as revenue when they are received or receivable. Restricted contributions are recorded as deferred revenue and recognized as revenue when the related expenses are incurred.

Contributions restricted for the acquisition of capital assets are recorded as deferred capital contributions and recognized as revenue over the estimated useful life of the related capital assets.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

1. Significant accounting policies (continued):

(b) Revenue recognition (continued):

Interest and dividend revenue and realized gains and losses on investments are recognized in the period earned. Unrealized gains and losses on investments are recorded in the period in which they occur.

(c) Expenses:

The Institute classifies expenses on the statement of operations by function. Expenses are recognized in the year incurred and are recorded in the applicable function to which they are related. The Institute does not allocate expenses between functions after initial recognition.

(d) Financial instruments:

Financial instruments are recorded at fair value on initial recognition and are subsequently recorded at cost or amortized cost unless management has elected to carry the instruments at fair value. Management has elected to carry its investments at fair value, with the exception of shares in private companies acquired by the Institute in exchange for patent or license rights, which are recorded at nominal value when the fair value of the transaction is not determinable.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the effective interest rate method.

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Institute determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Institute expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

(e) Capital assets:

Capital assets are stated at cost. Construction in progress comprises construction and development costs capitalized during the construction period. Contributed equipment is recorded at fair value at the date of contribution. Amortization is calculated on a straight-line basis over the estimated useful lives of the assets. Construction in progress assets are not amortized until the project is complete and the assets come into use.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

1. Significant accounting policies (continued):

(e) Capital assets (continued):

The estimated useful lives of the assets are as follows:

Asset	Useful life
Furniture and fixtures	5 years
Information system equipment	5 years
Laboratory equipment	5 to 10 years
Stem Cell and Vision Research floors	21 years

Patents are recorded at nominal value and are not amortized.

Capital assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When the capital asset no longer has any long-term service potential, the excess of its net carrying amount over its residual value is expensed.

(f) Foreign exchange:

Transactions conducted in a foreign currency are translated into Canadian dollars at the exchange rate in effect at the date of the transaction. Assets and liabilities denominated in foreign currencies are translated at exchange rates in effect at year-end. Foreign exchange gains and losses are recorded in the statement of operations.

(g) Use of estimates:

The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from these estimates. These estimates are reviewed annually and, as adjustments become necessary, they are reported in the periods in which they become known.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

2. Related entities:

Related party transactions are in the normal course of operations and are measured at the exchange amount which is the amount of consideration established and agreed to by the related parties. The Institute has no control over these related parties.

(a) The Ottawa Hospital:

The Ottawa Hospital acts as paymaster for the Institute. The Institute has an amount owing to The Ottawa Hospital of \$11,334,571 (2024 - \$7,995,440). This balance represents the difference between funds deposited at the Hospital and disbursements made on behalf of the Institute at year-end.

The Ottawa Hospital provided the Institute with grants as follows:

	2025	2024
General operating	\$ 4,981,596	\$ 4,929,561
Specific purpose operating	150,000	150,000
	<hr/> <u>\$ 5,131,596</u>	<hr/> <u>\$ 5,079,561</u>

TOH contributed \$1,000,000 at March 31, 2025 (2024 - \$2,000,000) to support the expansion of clinical research.

The unearned income balance remaining at March 31, 2025 is \$7,000,000 (2024 - \$7,000,000) from The Ottawa Hospital and \$389,777 (2024 - \$857,096) from miscellaneous unearned income.

(b) The Ottawa Hospital Foundation:

The Foundation provides administrative and research funding to the Institute. During the year, the Foundation contributed the following:

	2025	2024
Unrestricted research and salary funding	\$ 3,319,405	\$ 4,756,227
Unrestricted endowment fund interest	1,328,406	1,306,280
Restricted endowment fund interest for research projects	737,990	540,947
Restricted research project funding	2,716,178	2,302,676
Deferred capital contributions	1,092,286	80,024
	<hr/> <u>\$ 9,194,265</u>	<hr/> <u>\$ 8,986,154</u>

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

2. Related entities (continued):

(b) The Ottawa Hospital Foundation (continued):

At year-end, \$4,661,806 (2024 - \$4,814,316) of the total funding from the Foundation was receivable from the Foundation.

During fiscal year 2024, the Institute received a non-interest bearing loan of \$1,500,000 from the Foundation to aid in the support of the purchase of new technology for the New Campus Development project. During the year, there was an amendment to the agreement that changed the amounts due at maturity in September 2026 from \$1,500,000 to \$750,000 due April 30, 2026 and \$750,000 due April 30, 2027.

At March 31, 2025, the Foundation manages funds in the amount of \$61,477,994 (2024 - \$58,368,070), which are designated as Ottawa Hospital Research Institute Endowment Funds. While these funds have been designated to the Institute, they are legally the assets of the Foundation. Of this amount, \$1,010,399 (2024 - \$963,485) is restricted for the Clinical Epidemiology Unit Director's Research Chair.

(c) The University of Ottawa:

The University of Ottawa contributed \$1,947,795 (2024 - \$2,098,187) during the year to the Institute for salary support.

At March 31, 2025, endowment funds in the amount of \$1,772,113 (2024 - \$1,759,433) for the Clinical Epidemiology Unit Director's Research Chair are held by the University of Ottawa. During the year, the Institute received \$56,375 (2024 - \$56,375) of endowment fund income on these endowments.

Certain granting agencies (Canada Foundation for Innovation, Natural Sciences and Engineering Research Council of Canada and Canada First Research in Excellence) require that their funding flow via an Academic University setting. These funds are then transferred subsequently to the Institute. During the year, The University of Ottawa received \$3,910,541 (2024 - \$2,679,789) on behalf of the Institute's scientists.

The University provides premises and related maintenance and repairs to the Institute's on-site researchers at no charge. These amounts are not included in these financial statements.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

3. Amounts receivable:

	2025	2024
Current amounts receivable:		
Universities	\$ 4,404,311	\$ 6,104,560
Hospitals, Charities, Foundations	2,445,622	3,842,370
Government of Canada & other provincial governments	1,994,706	2,299,096
Corporations	1,394,601	1,825,526
Other	106,695	38,078
	10,345,935	14,109,630
Long-term amounts receivable:		
Corporations and other funders	1,559,104	1,169,329
Total amounts receivable	\$ 11,905,039	\$ 15,278,959

In the prior year, the Institute entered into a five-year innovation collaboration agreement with Lumenix involving the implementation and testing of Lumenix Aims Technology. The Institute pays for the licensing fees to operate the technology and in turn will receive royalty payments and a minimum collaboration rebate beginning in year three of the agreement. Lumenix has guaranteed a minimum of \$2,600,000 in revenue to OHRI throughout the term of the agreement. As at March 31, 2025, \$1,559,104 (2024 - \$1,169,329) has been recorded as a receivable.

4. Investments:

(a) Short-term investments:

Short-term investments consist of a Guaranteed Investment Certificate ("GIC") with a maturity date of September 26, 2025 at 3.28% and stock in company Satellos which had not yet been sold at year-end.

As at March 31, 2025, the market value of the Institute's short-term investments is \$7,089,754 (2024 - \$7,000,000) and Satellos shares is \$89,506 (2024 - \$Nil).

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

4. Investments (continued):

(b) Long-term investments:

The following table presents the fair values and related cost of the Institute's investments:

	2025 Fair value	2025 Cost	2024 Fair value	2024 Cost
Cash	\$ 143,327	\$ 143,324	\$ 96,630	\$ 96,630
Bonds/fixed income funds	68,272,624	73,698,554	59,389,089	68,331,766
Equity funds/pooled funds	67,378,342	62,207,872	60,317,368	57,990,679
Real estate	9,776,227	9,737,310	12,392,417	12,140,616
Shares in private companies	1	1	1	1
Shares in Boreal Biomanufacturing Inc.	100	100	100	100
Management fees payable	(272,000)	(272,000)	(281,681)	(281,681)
	\$ 145,298,621	\$ 145,515,161	\$ 131,913,924	\$ 138,278,111

At year-end, \$272,000 (2024 - \$281,681) was payable to Mercer Global Investments Canada Ltd ("MGI") through the investment portfolio.

The Institute holds shares in private companies that were received in exchange for an amendment to a patent/license agreement previously negotiated and in other cases, patent/license agreements to be negotiated. These shares do not give the Institute the ability to significantly influence or exercise control over these private companies. The shares are recorded in these financial statements at a nominal value as the value of the consideration given or received could not be determined. The fair value of these shares in private companies is not determinable.

The Institute controls Boreal Biomanufacturing Inc. a wholly-owned, profit-oriented subsidiary which was incorporated on December 20, 2021 under the Canada Corporations Act. The corporation has a primary focus on manufacturing biotherapeutics. There has not been any activity to date in the entity.

The bonds/fixed income funds have interest rates ranging from 0.00% to 21.78% (2024 - 0.00% to 21.00%) and maturity dates ranging from 2025 to 2085 (2024 - 2024 to 2099).

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

4. Investments (continued):

(b) Long-term investments (continued):

(i) Investment income:

	2025	2024
Realized gains, dividends and interest on investments	\$ 7,237,055	\$ 3,498,924
Unrealized gains on investments	6,147,642	8,162,991
Bank interest	1,585,523	1,811,001
	<hr/> \$ 14,970,220	<hr/> \$ 13,472,916

5. Capital assets:

	Cost	Accumulated amortization	Net book value	2025	2024
Furniture and fixtures	\$ 1,431,498	\$ 1,431,498	\$ —	\$ —	\$ —
Information system equipment	148,656	99,300	49,356	73,595	
Laboratory equipment	68,652,723	53,477,970	15,174,753	13,531,663	
Stem Cell and Vision Research floors	26,631,732	22,640,300	3,991,432	4,546,127	
Patents	1	—	1	1	
Construction-in-progress	245,207	—	245,207	697,355	
	<hr/> \$ 97,109,817	<hr/> \$ 77,649,068	<hr/> \$ 19,460,749	<hr/> \$ 18,848,741	

Cost and accumulated amortization of capital assets as at March 31, 2024 amounted to \$92,185,203 and \$73,336,462, respectively.

During the year ended March 31, 2025, the Institute disposed of equipment with a cost of \$3,925 (2024 - \$1,043,897) and accumulated amortization of \$2,393 (2024 - \$691,401) for proceeds of \$Nil (2024 - \$Nil), resulting in a loss of \$1,534 (2024 - \$352,946). The Institute also recognized deferred capital contribution grants for \$3,925 (2024 - \$1,043,897) and reversed accumulated amortization of \$2,393 (2024 - \$691,401) resulting in an offsetting gain of \$1,534 (2024 - \$352,946).

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

6. Unexpended research project funding:

Unexpended research project funding represents amounts received by the Institute which will be used in subsequent periods on active research projects. Changes in the unexpended research project funding balance are as follows:

	2025	2024
Balance, beginning of year	\$ 137,384,256	\$ 136,662,913
Amounts received in the current period	112,667,945	103,108,549
	250,052,201	239,771,462
Less:		
Research project costs	(103,446,220)	(99,368,787)
Amount transferred to deferred capital contributions	(4,924,614)	(3,018,419)
Balance, end of year	\$ 141,681,367	\$ 137,384,256

7. Deferred capital contributions:

	2025	2024
Balance, beginning of year	\$ 18,715,821	\$ 18,940,062
Additions (note 6)	4,924,614	3,018,419
Amortization	(4,268,299)	(3,242,660)
Balance, end of year	\$ 19,372,136	\$ 18,715,821

Included in deferred capital contributions is \$245,207 (2024 - \$697,355) related to the construction-in-progress.

8. Net assets:

The Institute considers its capital to consist of its unrestricted net assets, internally restricted net assets and its net assets invested in capital assets. The Institute's overall objective with its capital is to fund capital asset acquisitions, ongoing operations, and future health research. The Institute is not subject to externally imposed capital requirements and its overall definition and strategy with respect to capital remains unchanged from the year ended March 31, 2024.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

8. Net assets (continued):

(a) Internally restricted net assets:

The purpose of internally restricted net assets is to provide stability and funding for unforeseen events. The balance of internally restricted net assets consists of:

	2025	2024
Equalization Fund	\$ 22,009,848	\$ 22,009,848
Trainee Initiatives	95,278	68,000
Clinical Trials Support Unit	138,750	—
	<hr/>	<hr/>
	\$ 22,243,876	\$ 22,077,848

(i) Equalization Fund:

The Equalization Fund was established by the Board of Directors to provide the Institute with stable investment income for short-term and long-term budget planning. On an annual basis, Management along with the investment managers set a budgeted return on investments, which is approved by the Board. Actual investment income in excess of the budgeted amount, to the maximum of net income for the year, is transferred to the Equalization Fund. When actual investment income is less than the budgeted amount, the difference up to the maximum of the balance of the Equalization Fund or the Institute's net loss is transferred to the unrestricted net assets from the Equalization Fund.

During the year, \$Nil was transferred to the Equalization Fund from unrestricted net assets due to the equalization fund reaching its maximum threshold based on the Investment Stabilization Fund Policy (2024 - \$6,927,340 was transferred to the Equalization Fund from unrestricted net assets).

(ii) Trainee Initiatives:

During the year, the Trainee Initiatives Fund was established for specific trainee initiatives supported by a donation from the Foundation.

During the year, \$50,000 (2024 - \$68,000) was transferred to the Trainee Initiatives Fund from unrestricted net assets. During the year, \$22,722 (2024 - \$Nil) was transferred out of the Trainee Initiative Fund to the unrestricted net assets.

(iii) Clinical Trials Support Unit:

During the year, the Clinical Trials Support Unit Fund was established to enhance and strengthen clinical trials to benefit patient care and treatment supported by a donation from the Foundation.

During the year, \$138,750 (2024 - \$Nil) was transferred to the Clinical Trials Support Unit Fund from unrestricted net assets.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

8. Net assets (continued):

(b) Invested in capital assets:

The purpose of the Institute's net assets invested in capital assets is to fund the past acquisition of capital assets required for operational purposes.

The Institute's net assets invested in capital assets is calculated as follows:

	2025	2024
Capital assets (note 5)	\$ 19,460,749	\$ 18,848,741
Amounts financed by:		
Deferred contributions related to capital assets (note 7)	(19,372,136)	(18,715,821)
	\$ 88,613	\$ 132,920

9. Pension plan:

Substantially all of the full-time employees of the Institute are members of the Healthcare of Ontario Pension Plan (the "Plan"), which is a multi-employer defined benefit pension plan available to all eligible employees of the participating members of the Ontario Hospital Association. Plan members will receive benefits based on the length of service and on the average of annualized earnings during the five consecutive years prior to retirement, termination or death that provide the highest earnings.

Pension assets consist of investment grade securities. Market and credit risk on these securities are managed by the Plan by placing plan assets in trust and through the Plan investment policy.

Pension expense is based on Plan management's best estimates, in consultation with its actuaries, of the amount, which is currently calculated as 1.26 times the employees' pension contribution, required to provide a high level of assurance that benefits will be fully represented by fund assets at retirement, as provided by the Plan. The funding objective is for employer contributions to the Plan to remain a constant percentage of employees' contributions.

Variances between actuarial funding estimates and actual experience may be material and any differences are generally to be funded by the participating members. The most recent actuarial valuation of the Plan as at December 2024 indicates the Plan is fully funded. Contributions to the Plan made during the year by the Institute on behalf of its employees amounted to \$5,100,446 (2024 - \$4,754,422) and are recorded as an expense in the statement of operations.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

10. Financial instruments:

Financial risk factors:

The Institute's activities expose it to a variety of financial risks: market risk (including interest rate, currency (foreign exchange), and other price risks), credit risk and liquidity risk. Investments are held for liquidity purposes, or for longer terms, to achieve the highest possible rate of return consistent with the investment policies approved by the Board of Directors. The Institute does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes.

(a) Credit risk:

Credit risk refers to the risk that a counterparty may default on its contractual obligations resulting in a financial loss. The Institute is exposed to this risk relating to its cash, amounts receivable, and investments.

The Institute holds its cash accounts with federally regulated chartered banks who are insured by the Canadian Deposit Insurance Corporation. The Institute's receivables are primarily with governments, government funding agencies, corporate entities as disclosed in note 3. Management does not believe it is exposed to any significant credit risk as receivables are primarily from related parties and government organizations.

(b) Liquidity risk:

Liquidity risk is the risk that the Institute will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Institute manages its liquidity risk by monitoring its operating requirements. The Institute prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

(c) Market risk:

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate as a result of market factors. Market factors include three types of risk: currency risk, interest rate risk and other price.

(i) Currency risk:

Foreign currency risk refers to the extent to which instruments denominated in a currency other than Canadian dollars will be affected by changes in the value of the Canadian dollar in relation to other currencies. This exposure arises from the Institute's holdings of foreign cash balances, equities, and bonds. From time to time the Institute has investments in various U.S. securities and cash, which are subject to foreign currency risk. The Institute's exposure to investments denominated in U.S. currencies is \$35,108,361 (2024 - \$32,612,259). The Institute does not hedge its foreign currency risk.

OTTAWA HOSPITAL RESEARCH INSTITUTE

Notes to Financial Statements (continued)

Year ended March 31, 2025

10. Financial instruments (continued):

(c) Market risk (continued):

(ii) Interest rate risk:

Interest rate risk refers to the adverse consequences of interest rate changes on the Institute's cash flows, financial position and investment revenue. Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Investment practices are designed to avoid undue risk of loss or impairment to assets and provide a reasonable expectation of fair return given the nature of the investment. The Institute has investments in bonds with fixed rates which are subject to this risk, as the value of fixed rate instruments will generally rise if interest rates fall and fall if interest rates rise.

(iii) Other price risk:

Other price risk is the uncertainty associated with the valuation of assets arising from changes in equity markets. The Institute is exposed to this risk through its equity holdings within its investment portfolio as disclosed in note 4. The Institute manages other price risk through diversification of its investments and regular monitoring of investment performance.

The Institute's financial risks have increased during the year due to rising interest rates and market price fluctuations. Management believes that these financial risks are appropriately mitigated and do not pose significant risk to the Institute's on-going operations. There have been no significant changes in the policies, procedures, and methods used to manage these risks in the year.